Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group.

Clinical Colorectal Cancer
Catherine DunnMatthew Burge

Abstract

Palliative chemotherapy is the cornerstone of treatment for the majority of patients with metastatic colorectal cancer, with the aim of increasing length and quality of life. Although guidelines outline the available treatment options in the first line, they provide limited guidance on choice and intensity of the chemotherapy backbone. Data from the TRIBE and TRIBE2 studies confirm a survival benefit with triplet FOLFOXIRI and bevacizumab, and this is a preferred option for younger patients with good performance status able to tolerate it. However, the relative benefit of a fluoropyrimidine doublet with oxaliplatin or irinotecan over single-agent fluoropyrimidine with or without a biologic is less certain; the available data demonstrate that single-agent fluoropyrimidine plus a biologic with planned sequencing of subsequent agents can produce similar overall survival outcomes with reduced toxicity. Our analysis of local real-world registry data suggests that this is an underutilized approach, particularly in younger and fitter patients. Established prognostic factors, including patient age, performance status, tumor sidedness, and biomarkers such as RAS/BRAF, are key in treatment selection; patients with left-sided RAS/BRAF wil...Continue Reading

References

Feb 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·B UllmanD V Santi
Nov 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN Meta-Analysis Group In CancerP Thirion
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S GiacchettiF Lévi
Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A de GramontA Bonetti
Sep 28, 2000·The New England Journal of Medicine·L B SaltzL L Miller
Mar 12, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C H KöhneH Hecker
Mar 30, 1957·Nature·C HEIDELBERGERJ SCHEINER
Dec 6, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe TournigandAimery de Gramont
Dec 11, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard M GoldbergSteven R Alberts
Sep 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P ThirionUNKNOWN Meta-Analysis Group in Cancer
Mar 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fairooz F KabbinavarWilliam F Novotny
Jun 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giuseppe ColucciUNKNOWN Gruppo Oncologico Dell'Italia Meridionale
Jun 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C-H KöhneUNKNOWN European Organisation for Research and Treatment of Cancer Gastrointestinal Group
Apr 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce J GiantonioUNKNOWN Eastern Cooperative Oncology Group Study E3200
Jul 17, 2007·Lancet·Matthew T SeymourUNKNOWN National Cancer Research Institute Colorectal Clinical Studies Group
Oct 16, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Axel GrotheyMark Kozloff
Mar 25, 2009·Cancer·Yu-Ning WongJ Robert Beck
May 2, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Van CutsemUNKNOWN First BEAT investigators
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Niall C TebbuttTimothy J Price
May 17, 2011·Lancet·Matthew T SeymourUNKNOWN National Cancer Research Institute Colorectal Cancer Clinical Studies Group
Sep 10, 2011·The Lancet Oncology·Michel DucreuxUNKNOWN Fédération Francophone de Cancérologie Digestive (FFCD) 2000–05 Collaborative Group
Mar 1, 2012·Asia-Pacific Journal of Clinical Oncology·Timothy J PriceChristos S Karapetis
Jun 27, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M VoskoboynikP Gibbs
Nov 22, 2012·The Lancet Oncology·Jaafar BennounaUNKNOWN ML18147 Study Investigators
Sep 6, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Van CutsemUNKNOWN ESMO Guidelines Working Group
Oct 23, 2014·The New England Journal of Medicine·Fotios LoupakisAlfredo Falcone
May 13, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J SastreUNKNOWN Spanish Cooperative Group for the Treatment of Digestive Tumours TTD
Oct 22, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T AparicioUNKNOWN FFCD investigators
Dec 22, 2017·Journal of the National Cancer Institute·Katrin M SjoquistUNKNOWN Fondation Aide et Recherche en Cancerologie Digestive Group (ARCAD)
Nov 6, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dominik Paul ModestUNKNOWN XELAVIRI/AIO KRK0110 Investigators
Oct 1, 2019·The New England Journal of Medicine·Scott KopetzJosep Tabernero
Oct 1, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C CremoliniA Falcone
Jun 5, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Van CutsemV Moiseenko
Aug 5, 2020·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Annika KurreckDominik P Modest
Aug 21, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chiara CremoliniMassimo Di Maio

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.